RCT in 492 patients with rheumatoid arthritis after failure of one TNF inhibitor: switching to upadacitinib achieved DAS28-CRP ≤3.2 at 12 weeks more often than adalimumab (43.3% vs 22.4%; P<.0001); HAQ-DI did not differ. Safety was comparable.
RCTn = 492 patients
Mysler et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study